{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:05Z","timestamp":1790664245560,"version":"4.1.0"},"reference-count":111,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0129383","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T14:01:14Z","timestamp":1434549674000},"page":"e0129383","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":81,"title":["A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity"],"prefix":"10.1371","volume":"10","author":[{"given":"Laura","family":"Pertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Steinwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Hausberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"P\u00f6schl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Wackernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuf","family":"El-Shabrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity","volume":"41","author":"ME Hartnett","year":"2014","journal-title":"Clin Perinatol"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"C Gilbert","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","article-title":"Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years","volume":"44","author":"E McLoone","year":"2007","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-620X.142592","article-title":"Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity","volume":"7","author":"PK Shah","year":"2014","journal-title":"Oman J Ophthalmol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","article-title":"Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity","volume":"131","author":"C Karaca","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clp.2013.02.002","article-title":"The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment","volume":"40","author":"LE Smith","year":"2013","journal-title":"Clin Perinatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S11650","article-title":"Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity","volume":"4","author":"R Velez-Montoya","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1167\/iovs.12-11291","article-title":"Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF\/VEGFR2 pathway","volume":"54","author":"H Liu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","article-title":"Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors","volume":"88","author":"HA Mintz-Hittner","year":"2012","journal-title":"Early Hum Dev"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.sjopt.2014.07.001","article-title":"Vascular endothelial growth factor (VEGF-634G\/C) polymorphism and retinopathy of prematurity: a meta-analysis","volume":"28","author":"MA Malik","year":"2014","journal-title":"Saudi J Ophthalmol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"DK Wallace","year":"2013","journal-title":"Clin Perinatol"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"AL H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"R Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"T Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum Levels of Vascular Endothelial Growth Factor and Related Factors After Intravitreous Bevacizumab Injection for Retinopathy of Prematurity. JAMA Ophthalmol. 2015 Jan 8.","DOI":"10.1001\/jamaophthalmol.2014.5373"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of Bevacizumab and its Effects on Serum VEGF and IGF-1 in Infants with Retinopathy of Prematurity (ROP). Invest Ophthalmol Vis Sci. 2015 Jan 22.","DOI":"10.1167\/iovs.14-15842"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Schmid MK, Bachmann LM, F\u00e4s L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2014 Jun 11. pii: bjophthalmol-2014-305149.","DOI":"10.1136\/bjophthalmol-2014-305149"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis","volume":"132","author":"M Thulliez","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"ref19","first-page":"160","article-title":"Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients","volume":"112","author":"M A Bancalari","year":"2014","journal-title":"Arch Argent Pediatr"},{"key":"ref20","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison Between Ranibizumab and Bevacizumab. Retina. 2014 Dec 1. [Epub ahead of print]."},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"YH Chen","year":"2014","journal-title":"Eye (Lond)"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Cheng HC, Lee SM, Hsieh YT, Lin PK. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Retina. 2014 Oct 13. [Epub ahead of print]","DOI":"10.1097\/IAE.0000000000000359"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"MM Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"BC Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"A Henaine-Berra","year":"2014","journal-title":"J AAPOS"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10384-014-0310-z","article-title":"Intravitreal injection of bevacizumab for retinopathy of prematurity","volume":"58","author":"K Kuniyoshi","year":"2014","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity: Report on Fluorescein Angiographic Findings","volume":"121","author":"D Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"S Moran","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity","volume":"53","author":"AG Salman","year":"2014","journal-title":"Ophthalmic Res"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201427 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2014 Dec 14.","DOI":"10.1007\/s00417-014-2867-0"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"MA Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"BC Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"MA Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ped.12124","article-title":"Intravitreal bevacizumab monotherapy for retinopathy of prematurity","volume":"55","author":"A \u015eahin","year":"2013","journal-title":"Pediatr Int"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan","volume":"155","author":"WC Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3109\/14767058.2012.684109","article-title":"Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series","volume":"25","author":"C Dani","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","article-title":"Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"BC Harder","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"R Axer-Siegel","year":"2011","journal-title":"Retina"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"BC Harder","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"HA Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"4 Suppl","key":"ref41","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"P Dorta","year":"2010","journal-title":"Retina"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"HA Mintz-Hittner","year":"2008","journal-title":"Retina"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study","volume":"126","author":"L Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"BJ Lee","year":"2012","journal-title":"Eye (Lond)"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"S Ittiara","year":"2013","journal-title":"J AAPOS"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"RD Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","article-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?","volume":"91","author":"U Spandau","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3928\/01913913-20101217-06","article-title":"Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity","volume":"47","author":"KK Suk","year":"2010","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"Suppl 4","key":"ref49","first-page":"S70","article-title":"Intravitreal bevacizumab injection in advanced retinopathy of prematurity","volume":"95","author":"J Choovuthayakorn","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, et al. Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity. Curr Eye Res. 2014 Jul 15:1\u20137.","DOI":"10.3109\/02713683.2014.941070"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000368298","article-title":"Intravitreal injection of bevacizumab for retinopathy of prematurity in an infant with peters anomaly","volume":"5","author":"T Minami","year":"2014","journal-title":"Case Rep Ophthalmol"},{"issue":"8","key":"ref52","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/archophthalmol.2010.145","article-title":"Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment","volume":"128","author":"QV Hoang","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"ref53","first-page":"e66","article-title":"A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity","volume":"51","author":"Y Yaz","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaapos.2014.03.011","article-title":"Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser","volume":"18","author":"W Chen","year":"2014","journal-title":"J AAPOS"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ICB.0b013e318285238e","article-title":"Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity","volume":"7","author":"S Mehta","year":"2013","journal-title":"Retin Cases Brief Rep"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"SY Jang","year":"2010","journal-title":"J AAPOS"},{"issue":"8","key":"ref57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"J Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"LC Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"issue":"7","key":"ref59","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"S Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/08820538.2013.835842","article-title":"Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7","volume":"29","author":"J Chhablani","year":"2014","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5","volume":"98","author":"S Jalali","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":"Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage","volume":"248","author":"H Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"ref63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/jp.2009.166","article-title":"Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity","volume":"30","author":"LO Atchaneeyasakul","year":"2010","journal-title":"J Perinatol"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"S Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","article-title":"Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity","volume":"34","author":"J Kim","year":"2014","journal-title":"Retina"},{"issue":"11","key":"ref66","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"EJ Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"ref67","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":"Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels","volume":"248","author":"JY Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"ref68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"PK Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/0036933013496933","article-title":"Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report","volume":"58","author":"PW Flavahan","year":"2013","journal-title":"Scott Med J"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/eye.2013.148","article-title":"Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity","volume":"27","author":"TA de Klerk","year":"2013","journal-title":"Eye (Lond)"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000338623","article-title":"Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity","volume":"3","author":"A Mota","year":"2012","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"A Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3928\/01913913-20130528-03","article-title":"Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab","volume":"50","author":"DR Goldman","year":"2013","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"Suppl 3","key":"ref74","first-page":"S15","article-title":"Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP)","volume":"94","author":"B Wutthiworawong","year":"2011","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"ref75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0974-9233.65500","article-title":"Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity","volume":"17","author":"AE Ahmed","year":"2010","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"5","key":"ref76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/IAE.0b013e3181a3b848","article-title":"Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab","volume":"29","author":"NI Nonobe","year":"2009","journal-title":"Retina"},{"issue":"4","key":"ref77","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1111\/aos.12055","article-title":"Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection","volume":"91","author":"Y Xu","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"ref78","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcjo.2013.12.014","article-title":"Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity","volume":"49","author":"D Ehmann","year":"2014","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"ref79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"JC Law","year":"2010","journal-title":"J AAPOS"},{"issue":"3 Suppl","key":"ref80","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"H Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"issue":"9","key":"ref81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00417-011-1678-9","article-title":"Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series","volume":"249","author":"R Roohipoor","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"ref82","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"R Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"ref83","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan","volume":"118","author":"WC Wu","year":"2011","journal-title":"Ophthalmology"},{"issue":"3 Suppl","key":"ref84","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"GA Lalwani","year":"2008","journal-title":"Retina"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Altinsoy HI, Mutlu FM, G\u00fcng\u00f6r R, Sarici SU. Combination of Laser Photocoagulation and Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging. 2010 Mar 9:1\u20135","DOI":"10.3928\/15428877-20100215-03"},{"issue":"2","key":"ref86","first-page":"228","article-title":"Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options","volume":"6","author":"FM Mutlu","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"ref87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"DJ Gunn","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"issue":"2","key":"ref88","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0161-6420(99)00042-1","article-title":"A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity","volume":"107","author":"MJ Banach","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"ref89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archopht.123.5.621","article-title":"Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity","volume":"123","author":"KA Rezai","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"ref90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mpa.2002.121452","article-title":"Clinical outcome of confluent laser photoablation for retinopathy of prematurity","volume":"6","author":"N Fallaha","year":"2002","journal-title":"J AAPOS"},{"issue":"2","key":"ref91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3928\/01913913-20100308-05","article-title":"Confluent laser photocoagulation for the treatment of retinopathy of prematurity","volume":"47","author":"VH Gonzalez","year":"2010","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"9","key":"ref92","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ophtha.2012.02.040","article-title":"Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity","volume":"119","author":"WC Wu","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"ref93","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.sjopt.2012.05.006","article-title":"Long term visual outcomes in laser treated threshold retinopathy of prematurity in Central Saudi Arabia","volume":"26","author":"AG Al-Otaibi","year":"2012","journal-title":"Saudi J Ophthalmol"},{"key":"ref94","unstructured":"Trese MT, Capone A Jr, Drenser K. Macugen in Retinopathy of Prematurity. EBM Reviews\u2014Cochrane Central Register of Controlled Trials. IOVS. Vol.47, pp.ARVO E-abstract 2330, 2006."},{"issue":"12","key":"ref95","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"26","key":"ref96","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"ME Hartnett","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"ref97","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"R Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"ref98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3341\/kjo.2014.28.1.32","article-title":"Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab","volume":"28","author":"D Wang","year":"2014","journal-title":"Korean J Ophthalmol"},{"issue":"5","key":"ref99","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/02713683.2013.848899","article-title":"Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration","volume":"39","author":"X Gu","year":"2014","journal-title":"Curr Eye Res"},{"issue":"1","key":"ref100","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"AM Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"ref101","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ajo.2014.06.009","article-title":"Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration","volume":"158","author":"X Wang","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"ref102","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00417-014-2717-0","article-title":"Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration","volume":"252","author":"I Yoshida","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2014 Dec 8.","DOI":"10.1111\/aos.12604"},{"key":"ref104","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"8","author":"SD Solomon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"ref105","doi-asserted-by":"crossref","first-page":"e41325","DOI":"10.1371\/journal.pone.0041325","article-title":"Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis","volume":"7","author":"JW Cheng","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"ref106","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","article-title":"RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study","volume":"121","author":"U Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"ref107","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"DF Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study","volume":"340","author":"A Tufail","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"ref109","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results","volume":"145","author":"AN Antoszyk","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"ref110","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"PJ Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"ref111","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/j.1755-3768.2012.02552.x","article-title":"What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?","volume":"91","author":"U Spandau","year":"2013","journal-title":"Acta Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0129383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:53:23Z","timestamp":1691751203000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0129383"}},"subtitle":[],"editor":[{"given":"Mary Elizabeth","family":"Hartnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":111,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0129383","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]}}}